EMOCARE Depression Thermometer Hits 90% Concordance, Rolls Out in Hope Clinics
NRXP•Emobot’s smartphone-based EMOCARE tool achieved 90% within-patient concordance with MADRS (r=0.895; p=0.016) and ρ=0.834 sensitivity versus PHQ-9 (p<0.001) in pooled analysis of three observational studies. The passive monitoring system is now deployed across Hope Therapeutics’ interventional psychiatry network as a self-monitoring safety-net tool.
1. Clinical Validation Demonstrates High Concordance
EMOCARE achieved 90% within-patient concordance with clinician-rated MADRS (r=0.895; p=0.016) and ρ=0.834 sensitivity to symptom changes against PHQ-9 (p<0.001) in a pooled analysis of three prospective observational studies involving major depressive and bipolar disorder patients.
2. Passive Monitoring Deployed in Hope Therapeutics Network
The smartphone-based tool passively tracks voice, facial expression, motion, and screen behavior to generate continuous depression scores and is now integrated across Hope Therapeutics’ interventional psychiatry clinics as a patient-facing monitoring and safety-net resource.
3. Strategic Benefits for NRx Pharmaceuticals
By coupling EMOCARE’s real-time assessment capabilities with interventional therapies like TMS and intravenous ketamine, NRx gains continuous visibility into patient responses between visits, aiming to reduce relapse timelines in treatment-resistant depression.
